Last reviewed · How we verify
CT071
At a glance
| Generic name | CT071 |
|---|---|
| Sponsor | CARsgen Therapeutics Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of CT071 Injection in RRMM or PPCL (EARLY_PHASE1)
- Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma (EARLY_PHASE1)
- Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |